NEJM Interviews
NEJM Interviews
NEJM Group
NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
2 minutes Posted Sep 15, 2024 at 3:01 pm.
0:00
2:58
Download MP3
Show notes
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.